From the Litigation Practice.
Off-label Drug and Device Promotion in the Wake of Amarin
February, 2017
Recent cases involving promotion to doctors have challenged off-label promotion enforcement actions based on due process and First Amendment grounds, as well as physicians’ need for scientific information. By Marisa A. Trasatti and Marie Claire Langlois
The above publication is saved in PDF format. You will need the free Adobe Acrobat Reader to view this document.